Johnlim Samba CEO "ADC Factory to be Completed in December... Will Achieve Super-Gap"

Samsung Biologics has expressed its commitment to continuing 'super-gap' growth by securing antibody-drug conjugate (ADC) technology and production capacity, the most notable anticancer drug platform in the global pharmaceutical and bio industry.

John Rim, CEO of Samsung Biologics, is speaking at the company's regular shareholders' meeting held on the 15th at Songdo Convensia in Yeonsu-gu, Incheon.
[Photo by Samsung Biologics]

John Rim, CEO of Samsung Biologics, stated at the company's regular shareholders' meeting held on the 15th at Songdo Convensia in Yeonsu-gu, Incheon, "The ADC dedicated production facility is scheduled to be completed in December," adding, "We are actively investing in securing production capacity and technological capabilities to establish competitiveness in the ADC field, which is emerging as the next-generation bio technology, and to proactively respond to the market." Samsung Biologics is continuing collaborations not only for production facilities but also for securing related technologies with Swiss Araris and domestic companies LegoChemBio and AimedBio.

Regarding this, CEO Rim said, "Despite the challenging management environment over the past year, we recorded excellent performance," emphasizing, "Although a difficult management environment is expected to continue this year, we will not stop our challenge toward becoming a global top-tier bio company." Samsung Biologics recorded consolidated sales of KRW 3.6946 trillion and operating profit of KRW 1.1137 trillion last year. Sales increased by 23% and operating profit by 13% compared to the previous year. The operating profit margin reached 30%.

John Rim, CEO of Samsung Biologics, is speaking at the company's regular shareholders' meeting held on the 15th at Songdo Convensia in Yeonsu-gu, Incheon.
[Photo by Lee Chunhee]

This year, the company announced the start of its order-winning battle by signing contracts with Belgian pharmaceutical company UCB and global big pharma MSD of the United States earlier this month. The cumulative orders this year amount to $423.24 million (approximately KRW 474.7 billion), which is similar to the pace of last year's record-high order performance since the company's founding, indicating that the order-winning strategy is progressing smoothly.

Samsung Biologics also plans to maintain its super-gap in production capacity for its existing core industry, antibody drugs. Through plants 1 to 4, Samsung Biologics has secured the world's largest production capacity of 604,000 liters. The 4th plant, which started full operation in June last year and has the world's largest single-plant production capacity of 240,000 liters, is "approaching full operation due to an increase in large-scale order volumes centered on big pharma," the company explained.

Not stopping there, starting with the 5th plant scheduled for completion in April next year, Samsung Biologics plans to additionally secure 720,000 liters of production capacity at the 2nd Bio Campus by 2032. Even before completion, pre-orders linked to contracts made with the 4th plant are already coming in for the 5th plant. The company is also considering expanding the 3rd Bio Campus in response to continued orders.

Meanwhile, at the shareholders' meeting held that day, the agenda to appoint former Minister of Land, Infrastructure and Transport Seo Seung-hwan as an outside director, replacing former Vice Minister of Strategy and Finance Ando-gul who resigned for personal reasons, was also passed. Former Vice Minister Ando is currently preparing to run for the National Assembly election in Gwangju.

This content was produced with the assistance of AI translation services.